An interventional study of Invasive coronary physiological measurements in Coronary Microvascular Dysfunction (CMD) and Vasospasm, Coronary, sponsored by Mid and South Essex NHS Foundation Trust. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Mid and South Essex NHS Foundation Trust · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn more about the diagnosis of coronary endothelium function and coronary vasospasm using a dedicated invasive protocol in patients who has angina without obstruction in their main heart arteries. The main question it aims to answer is the feasibility, reproducibility, and safety of this invasive protocol:
Does this invasive protocol diagnose coronary endothelial dysfunction and vasospasm without issues?
Participants already having invasive coronary angiogram and physiological studies will undergo additional physiological measurements during the same procedure.
Participants will enrol in a symptoms and quality of life questionnaire using dedicated questionnaires and a mobile application to assess the burden of their symptoms before and after the invasive procedure and up to 12 months follow up.
A subset of participants will undergo a repeat set of these measurements to assess reproducibility of the invasive protocol.
A subset of the participants will also undergo a cardiac MRI to assess correlation with the invasive protocol measurements.
27 studies on the registry are indexed under Coronary Vasospasm; 7 are open to participants now.
This study's planned enrollment of 100 is close to the median of 95 across 14 interventional studies indexed under Coronary Vasospasm.
Browse Coronary Vasospasm studies →Mid and South Essex NHS Foundation Trust is the lead sponsor of 34 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Invasive coronary endothelial function and vasospasm assessment
Procedure: Invasive coronary physiological measurements
Invasive assessment of changes in coronary blood flow, resistance, and distal pressure in response to acetylcholine infusion. These will be measured during a clinical indicated invasive coronary angiogram procedure and physiological studies using a standard coronary pressure wire and a dedicated infusion catheter.
Feasibility outcome
Proportion of patients in whom the full invasive protocol (baseline and post-stimulation measurements) is successfully completed without major technical issues or protocol deviations.
Time frame: At baseline
Reproducibility outcome
Intra- and inter-operator variability of measurements quantified using intraclass correlation coefficients and Bland-Altman plots in a predefined reproducibility subset.
Time frame: At baseline
Safety outcome
Incidence of adverse events related to the procedure or medications.
Time frame: At Baseline and up to 12 months
Correlation between invasive and non-invasive measures of endothelial-dependent coronary microvascular dysfunction.
Strength of correlation (unit of measure = correlation coefficient, r) between invasive indices of endothelial-dependent coronary microvascular function obtained during the study protocol (absolute coronary blood flow and absolute microvascular resistance measured by continuous thermodilution during intracoronary acetylcholine testing) and non-invasive measures of myocardial perfusion (myocardial perfusion reserve obtained from cardiac stress perfusion imaging). Diagnostic agreement for identifying endothelial-dependent microvascular dysfunction will also be assessed (unit of measure = area under ROC curve, sensitivity, and specificity), using the invasive assessment as the reference standard.
Time frame: From baseline and up to 3 months
Correlation between invasive physiological indices of coronary microvascular function and symptom burden at baseline.
The strength of correlation (Pearson or Spearman correlation coefficient; unit of measure = correlation coefficient, r) between invasive physiological measurements of coronary microvascular function obtained during the study protocol (e.g., absolute coronary blood flow and absolute microvascular resistance derived by continuous thermodilution during acetylcholine testing) and patient-reported symptom burden assessed at baseline using validated questionnaires (Seattle Angina Questionnaire-7 \[SAQ-7\] and EQ-5D-5L scores).
Time frame: Baseline (at time of invasive coronary function testing).
Change in symptoms, quality of life, and need for further investigation or treatment during follow-up.
Change from baseline to follow-up in patient-reported symptoms and quality of life (unit of measure = change in questionnaire score) as assessed using the SAQ-7 and EQ-5D-5L questionnaires, and the proportion of patients (%) requiring additional cardiac investigations or treatment changes during follow-up.
Time frame: From baseline to 12 months follow-up
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Dec 2026, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mid and South Essex NHS Foundation Trust